Which of the following best describes a Phase III clinical trial?
A study in which the investigator explores tolerability, safe dosage, side effects, and how the body copes with a drug |
||
A study involving animals or cell cultures |
||
A relatively large, randomized, blinded trial used to evaluate the efficacy of an intervention |
||
An unblinded, uncontrolled study with typically less than 30 volunteers that is conducted to determine the safety of a treatment in humans |
||
A large study conducted to assess the rate of serious side effects and explore further therapeutic uses of a therapy that already been approved by the FDA |
From the given information,
The correct answer is,
A large study conducted to assess the rate of serious side effects and explore further therapeutic uses of a therapy that already been approved by the FDA |
Thank you.
Which of the following best describes a Phase III clinical trial? A study in which the...
Clinical trials are usually conducted in phases that build on one another. Each phase is designed to answer certain questions. Knowing the phase of the clinical trial is important because it can give you some idea about how much is known about the treatment being studied. There are pros and cons to taking part in each phase of a clinical trial. Phase I clinical trials: Is the treatment safe? Phase I studies of a new drug are usually the first...
Identify the scientific premise, main hypothesis addressed by the paper and the research question of the paper Also, what is the main results and the implication of results IMPORTANCE Clinical outcomes for glioblastoma remain poor. Treatment with immune checkpoint blockade has shown benefits in many cancer types. To our knowledge, data from a randomized phase 3 clinical trial evaluating a programmed death-1 (PD-1) inhibitor therapy for glioblastoma have not been reported. OBJECTIVE To determine whether single-agent PD-1 blockade with nivolumab...
What should have Merck & Co, Inc done differently in regards to river blindness? Merck & Company, Inc.: Having the Vision to Succeed by Stephanie Weiss and David Bollier An Expensive Care for a Poor Market In 1978, Dr. P. Roy Vagelos, then head of the Merck research labs, received a provocative memorandum from a senior researcher in parasitology, Dr. William C. Campbell. Dr. Campbell had made an intriguing observation while working with ivennectin, a new antiparasitic compound under investigation...